From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes the company as having recently crossed into an approved/specified/listed status within buyers' systems, such that future business can arrive without discrete selling, and that this is new enough that most volume is ahead. Scan the transcript for relevant statements. Management discusses regulatory approvals, rate reviews, settlements, riders, etc. For example, Wyoming Electric settlement approved with transmission rider. Colorado Clean Energy Plan settlement with 400 MW renewable generation, half owned by utility, competitive bidding process expected to commence in Q2. South Dakota IRP proposing 100 MW renewables and battery storage, RFP later this quarter. Ready Wyoming transmission line approved, construction starting this year. Also blockchain customer in Cheyenne going into service shortly. But the question is about being placed into a buyer's purchasing system (like approved supplier list, formulary, etc.) such that orders come without selling. In utility context, this could be regulatory approvals that allow cost recovery, or being selected in a procurement process. However, the transcript mostly discusses regulatory approvals for rate cases, riders, and resource plans. These are not exactly "buyers' purchasing systems" in the sense of a customer's approved vendor list. The company is a utility, and its "buyers" are customers, but the regulatory approvals allow it to recover costs, not necessarily to be a default choice in a procurement system. The question specifically asks about "buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems." In the utility context, this could be like being selected in a competitive bidding process for renewable resources, or being approved for a tariff. But the transcript mentions that the Colorado Clean Energy Plan settlement includes a competitive bidding process for new resources, with utility owning half. That means the utility will participate in a bidding process, not that it is automatically placed into a system. The approval of the settlement is a regulatory approval, not a buyer-side system. Also, the company is a regulated utility, so its revenue comes from rate base and cost recovery, not from being on a supplier list. The concept of "default" or "pre-authorized" doesn't quite fit.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.